Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes
- PMID: 16156629
- DOI: 10.1021/ic0503737
Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes
Abstract
A series of mixed chloro-azole ruthenium complexes with potential antitumor activity, viz., mer-[RuIIICl3(azole)3] (B), trans-[RuIIICl2(azole)4]Cl (C), trans-[RuIICl2(azole)4] (D), and [RuII(azole)6](SO3CF3)2 (E), where azole = 1-butylimidazole (1), imidazole (2), benzimidazole (3), 1-methyl-1,2,4-triazole (4), 4-methylpyrazole (5), 1,2,4-triazole (6), pyrazole (7), and indazole (8), have been prepared as a further development of anticancer drugs with the general formula [RuCl4(azole)2]- (A). These compounds were characterized by elemental analysis, IR spectroscopy, electronic spectra, electrospray mass spectrometry, and X-ray crystallography. The electrochemical behavior has been studied in detail in DMF, DMSO, and aqueous media using cyclic voltammetry, square wave voltammetry, and controlled potential electrolysis. Compounds B and a number of C complexes exhibit one RuIII/RuII reduction, followed, at a sufficiently long time scale, by metal dechlorination on solvolysis. The redox potential values in organic media agree with those predicted by Lever's parametrization method, and the yet unknown EL parameters were estimated for 1 (EL = 0.06 V), 3 (EL = 0.10 V), 4 (EL = 0.17 V), and 5 (EL = 0.18 V). The EL values for the azole ligands 1-8 correlate linearly with their basicity (pK(a) value of the corresponding azolium acid H2L+). In addition, a logarithmic dependence between the homogeneous rate constants for the reductively induced stepwise replacement of chloro ligands by solvent molecules and the RuIII/RuII redox potentials was observed. Lower E(1/2) values (higher net electron donor character of the ligands) result in enhanced kinetic rate constants of solvolysis upon reduction. The effect of the net charge on the RuIII/RuII redox potentials in water is tentatively explained by the application of the Born equation. In addition, the pH-dependent electrochemical behavior of trans-[RuCl2(1,2,4-triazole)4]Cl is discussed.
Similar articles
-
Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.Inorg Chem. 2004 Nov 1;43(22):7083-93. doi: 10.1021/ic049479c. Inorg Chem. 2004. PMID: 15500346
-
Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.Inorg Chem. 2005 Jan 10;44(1):122-32. doi: 10.1021/ic048967h. Inorg Chem. 2005. PMID: 15627368
-
Diorganoruthenium complexes incorporating noninnocent [C(6)H(2)(CH(2)ER(2))(2)-3,5](2)(2-) (E = N, P) bis-pincer bridging ligands: synthesis, spectroelectrochemistry, and DFT studies.Inorg Chem. 2007 Dec 24;46(26):11133-44. doi: 10.1021/ic701501q. Epub 2007 Dec 1. Inorg Chem. 2007. PMID: 18052055
-
Electronic structure alternatives in nitrosylruthenium complexes.Dalton Trans. 2010 May 21;39(19):4471-8. doi: 10.1039/c002173c. Epub 2010 Mar 18. Dalton Trans. 2010. PMID: 20449468 Review.
-
Recent developments in ruthenium anticancer drugs.Metallomics. 2009 Nov;1(6):458-70. doi: 10.1039/b904071d. Epub 2009 Aug 13. Metallomics. 2009. PMID: 21305154 Review.
Cited by
-
En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2].Inorg Chem. 2011 Aug 15;50(16):7690-7. doi: 10.1021/ic200728b. Epub 2011 Jul 8. Inorg Chem. 2011. PMID: 21739939 Free PMC article.
-
The Ruthenium Nitrosyl Moiety in Clusters: Trinuclear Linear μ-Hydroxido Magnesium(II)-Diruthenium(II), μ3-Oxido Trinuclear Diiron(III)-Ruthenium(II), and Tetranuclear μ4-Oxido Trigallium(III)-Ruthenium(II) Complexes.Inorg Chem. 2022 Jan 17;61(2):950-967. doi: 10.1021/acs.inorgchem.1c03011. Epub 2021 Dec 28. Inorg Chem. 2022. PMID: 34962391 Free PMC article.
-
Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine.Bioinorg Chem Appl. 2010;2010:183097. doi: 10.1155/2010/183097. Epub 2010 Jun 2. Bioinorg Chem Appl. 2010. PMID: 20631838 Free PMC article.
-
Cytotoxic (salen)ruthenium(iii) anticancer complexes exhibit different modes of cell death directed by axial ligands.Chem Sci. 2017 Oct 1;8(10):6865-6870. doi: 10.1039/c7sc02205k. Epub 2017 Jul 31. Chem Sci. 2017. PMID: 29147511 Free PMC article.
-
Electronic structural investigations of ruthenium compounds and anticancer prodrugs.J Biol Inorg Chem. 2009 Aug;14(6):891-8. doi: 10.1007/s00775-009-0501-0. Epub 2009 Apr 7. J Biol Inorg Chem. 2009. PMID: 19350289
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous